<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811094</url>
  </required_header>
  <id_info>
    <org_study_id>2015-26</org_study_id>
    <secondary_id>2015-A00981-48</secondary_id>
    <nct_id>NCT02811094</nct_id>
  </id_info>
  <brief_title>LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse</brief_title>
  <acronym>LUMIER²</acronym>
  <official_title>LUMIER² Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We aim to determine the accuracy or blood transcriptomic signatures to predict the occurrence&#xD;
      of flares in patients with SLE that are clinically quiescent at inclusion Systemic Lupus&#xD;
      Erythematosus (SLE) is a chronic auto-immune disease evolving by flares, with possible organ&#xD;
      damage, and periods of remission. Current biological markers of disease activity are not&#xD;
      sufficient to predict the occurrence of flares, monitor response to treatment or adapt&#xD;
      therapeutic strategies. A previous study on genome-wide whole blood transcriptomic signatures&#xD;
      in SLE (Chiche et al, Arthritis Rheumatology 2014) has identified gene panels associated with&#xD;
      SLE disease activity&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic Lupus Erythematosus (SLE) is a chronic auto-immune disease evolving by flares, with&#xD;
      possible organ damage, and periods of remission. Current biological markers of disease&#xD;
      activity are not sufficient to predict the occurrence of flares, monitor response to&#xD;
      treatment or adapt therapeutic strategies. A previous study on genome-wide whole blood&#xD;
      transcriptomic signatures in SLE (Chiche et al, Arthritis Rheumatology 2014) has identified&#xD;
      gene panels associated with SLE disease activity.&#xD;
&#xD;
      We aim to determine the accuracy or blood transcriptomic signatures to predict the occurrence&#xD;
      of flares in patients with SLE that are clinically quiescent at inclusion.&#xD;
&#xD;
      LUMIER² is a prospective multicentric observational study conducted in the departments of&#xD;
      Clinical Nephrology, Internal Medicine and Rheumatology in the South of France. Adult&#xD;
      patients with SLE, clinically quiescent and with no change in treatment in the past 3 months,&#xD;
      will be included and followed-up for 12 months. Blood samples will be drawn every 3 months&#xD;
      during 12 months in the absence of flare. Patients presenting a flare will be sampled at the&#xD;
      time of the flare and 1 month later.&#xD;
&#xD;
      The inclusion of 300 patients is expected, with a test cohort (150 patients) and a validation&#xD;
      cohort (150 patients).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID situation&#xD;
  </why_stopped>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Actual">January 14, 2021</completion_date>
  <primary_completion_date type="Actual">January 14, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of the blood transcriptomic score to predict SLE flares.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">210</enrollment>
  <condition>Systemic Lupus Erythematosus (SLE)</condition>
  <arm_group>
    <arm_group_label>Adult patients with Systemic LupusErythematosus (SLE)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Adult patients with SLE, clinically quiescent and with no change in treatment in the past 3 months, will be included and followed-up for 12 months. Blood samples will be drawn every 3 months during 12 months in the absence of flare. Patients presenting a flare will be sampled at the time of the flare and 1 month later.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>polymerase chain reaction (PCR) technique of blood transcriptome analysis</intervention_name>
    <description>this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus</description>
    <arm_group_label>Adult patients with Systemic LupusErythematosus (SLE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  SLE defined by ACR criteria&#xD;
&#xD;
          -  Clinically quiescent disease (SLEDAI =&lt; 4 without clinical flare) and absence of&#xD;
             treatment increase in the past 3 months&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy, lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urielle DESALBRES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hôpitaux de Marseille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de la conception Assistance Publique Hôpitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

